Clinuvel Pharmaceuticals (CUV:ASX) Annual Reports & Investor Relations Material

Overview

Founded in 1987, Clinuvel is headquartered in Melbourne, Australia and has operations in Europe, Asia, and the United States. The company's flagship product, SCENESSE, is a first-of-its-kind photoprotective drug that is designed to treat patients with the genetic disorder, erythropoietic protoporphyria (EPP). SCENESSE, which was approved by the European Medicines Agency (EMA) in 2014, has significantly improved the quality of life for EPP patients by reducing their sensitivity to light and allowing them to engage in outdoor activities. Clinuvel has a strong pipeline of products, including treatments for genetic disorders such as xeroderma pigmentosum (XP) and metabolic disorders such as phenylketonuria (PKU). The company's goal is to expand its market reach and offer more solutions for patients with rare and underserved diseases around the world.

Frequently Asked Questions

What is Clinuvel Pharmaceuticals's ticker?

Clinuvel Pharmaceuticals's ticker is CUV

What exchange is Clinuvel Pharmaceuticals traded on?

The company's shares trade on the ASX stock exchange

Where are Clinuvel Pharmaceuticals's headquarters?

They are based in Melbourne, Australia

How many employees does Clinuvel Pharmaceuticals have?

There are 11-50 employees working at Clinuvel Pharmaceuticals

What is Clinuvel Pharmaceuticals's website?

It is clinuvel.com

What type of sector is Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is in the Healthcare sector

What type of industry is Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is in the Biotechnology industry

Who are Clinuvel Pharmaceuticals's peers and competitors?

The following five companies are Clinuvel Pharmaceuticals's industry peers:

- Aptinyx

- Citius Pharmaceuticals, Inc.

- Merus

- Aerpio Pharmaceuticals, Inc.

- Idera Pharmaceuticals, Inc.